|1.||Kishi, Masahiko: 2 articles (02/2015 - 04/2014)|
|2.||Tateno, Akihiko: 2 articles (02/2015 - 04/2014)|
|3.||Hirai, Shigekazu: 2 articles (02/2015 - 04/2014)|
|4.||Ogata, Tsuyoshi: 2 articles (02/2015 - 04/2014)|
|5.||Doi, Hirokazu: 2 articles (02/2015 - 04/2014)|
|6.||Tateno, Fuyuki: 2 articles (02/2015 - 04/2014)|
|7.||Masaka, Tohru: 2 articles (02/2015 - 04/2014)|
|8.||Tsuyusaki, Yohei: 2 articles (02/2015 - 04/2014)|
|9.||Sakakibara, Ryuji: 2 articles (02/2015 - 04/2014)|
|10.||Sato, Mitsutoshi: 2 articles (02/2015 - 04/2014)|
|1.||Duodenal Ulcer (Curling's Ulcer)
01/01/1987 - "Nizatidine proved to be safe and effective in preventing recurrences of duodenal ulcer."
03/01/1995 - "The aim of the present study was to assess the efficacy of a half-single nocturnal dose of nizatidine (150 mg at bedtime [h.s.], n = 40) with a standard full dose given once nightly (300 mg h.s., n = 38) or twice daily (150 mg twice a day [b.i.d.], n = 43) in the treatment of Chinese patients with active duodenal ulcers. "
01/01/1987 - "Nizatidine as maintenance therapy of duodenal ulcer disease in remission."
03/01/1995 - "Our study suggested that a half-single nocturnal dose of nizatidine is not ideal for the treatment of duodenal ulcer in Chinese patients, whereas a single standard nocturnal dose appears more effective than a twice-daily regimen."
01/01/1994 - "In duodenal ulcer (DU), the long-term nature of treatments and psychological status of patients make QoL studies of major interest, as exemplified by the nizatidine model."
|2.||Gastroesophageal Reflux (GERD)
01/01/2008 - "We experienced a patient with gastroesophageal reflux disease (GERD) and impaired salivary secretion who has been successfully treated with nizatidine. "
02/01/2002 - "Increased salivary secretion and bicarbonate output induced by nizatidine may be useful for the treatment of patients with gastro-oesophageal reflux disease."
10/01/2010 - "Multicenter, double-blind, placebo-controlled crossover study to assess the acute prokinetic efficacy of nizatidine-controlled release (150 and 300 mg) in patients with gastroesophageal reflux disease."
12/01/1999 - "Nizatidine appears to possess a prokinetic mechanism that may be helpful in treating patients with gastroesophageal reflux."
10/01/2010 - "The aim of the study is to test whether nizatidine delivered via a unique bimodal pulsatile-controlled release system, nizatidine controlled release (CR), accelerates gastric emptying in patients with gastroesophageal reflux disease (GERD). "
11/01/1994 - "Compared with placebo, nizatidine 150 mg twice daily was highly effective in rapidly reducing the severity of heartburn, regardless of oesophagitis severity at entry. "
11/01/1994 - "Twice-daily administration of nizatidine 150 mg or 300 mg provides prompt relief from the major symptom of GORD, heartburn, and complete healing of oesophagitis is seen in many patients."
07/28/1997 - "Single doses of 225 mg and 75 mg of nizatidine administered 30 minutes before a standard meal intended to provoke heartburn are significantly more effective than placebo for the prevention and/or reduction of postprandial heartburn."
11/01/1994 - "The nizatidine 150 mg treatment group had significantly greater improvement in daytime and nighttime heartburn severity after 1 day of therapy versus placebo. "
06/01/1992 - "The nizatidine 150 mg treatment group had significantly greater improvement in daytime and nighttime heartburn severity after one day of therapy versus placebo. "
01/01/1994 - "It is concluded that nizatidine is a safe and effective therapy for preventing DU recurrence in patients with endoscopically confirmed healed ulcers."
11/08/1993 - "This study showed that nizatidine, 150 mg, twice daily, significantly reduces the incidence of ulcer formation in high-risk patients taking long-term NSAID therapy. "
01/01/1992 - "[Modern trends in the treatment of ulcer disease (clinical study of nizatidine "Galitidine")]."
05/01/1995 - "Seven patients whose ulcer recurred after discontinuation of nizatidine were allocated to receive 2 weeks of triple therapy. "
10/01/1994 - "Nizatidine and placebo induced ulcer healing in 76% and 60.9% of the patients, respectively, but the difference did not reach statistical significance. "
07/01/2004 - "Nizatidine may be effective for reducing weight gain associated with both medical and psychiatric conditions. "
12/01/2006 - "Patients receiving placebo and nizatidine had a mean weight gain of 12.3% (0.7 kg) and 12% (1.1 kg) from baseline to endpoint, respectively (p = 0.9). "
07/01/2004 - "Based on a report of another patient who developed EPS after taking higher-than-recommended doses of nizatidine, we reviewed the literature on treatment with H2-receptor antagonists for weight gain and on central nervous system adverse effects of nizatidine. "
07/01/2004 - "Nizatidine, a histamine2 (H2)-receptor antagonist, may help reduce this weight gain. "
08/01/2003 - "A combination of nizatidine for 8 weeks resulted in significant reversal of weight gain without worsening the psychopathology (weight: 3.5% and BMI: 3.7%). "
|5.||Histamine (Histamine Dihydrochloride)
|10.||Acetylcholine (Acetylcholine Chloride)
|1.||Drug Therapy (Chemotherapy)
|3.||Renal Dialysis (Hemodialysis)